John A. Stalfort III - 01 Jun 2026 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
02 Jun 2026, 16:30:21 UTC
Prior SEC filing
05 Jun 2025
Next SEC filing
05 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Kamran Alam, Attorney-in-Fact

Key filing fact

John A. Stalfort III filed Form 4 for Taysha Gene Therapies, Inc. (TSHA) on 02 Jun 2026.

Key facts

  • This page summarizes John A. Stalfort III's Form 4 filing for Taysha Gene Therapies, Inc. (TSHA).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 02 Jun 2026, 16:30.

Change

  • Previous filing in this sequence was filed on 05 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001709418 Primary reporting owner

Stalfort John A III

Relationship
Director
Address
C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS
Signature
/s/ Kamran Alam, Attorney-in-Fact
Signature date
02 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TSHA transaction

Common Stock

Award

Transaction value
Shares
+21,335
Change %
+1.8%
Price
$0.000000*
Shares after
1,176,559
Date
01 Jun 2026
Ownership
Direct
Footnotes
F1
TSHA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
884,290
Date
01 Jun 2026
Ownership
See footnote
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TSHA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+42,671
Change %
Price
$0.000000*
Shares after
42,671
Date
01 Jun 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
42,671
Exercise price
$5.97
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Footnote F2

The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018.

Footnote F3

The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .